A hypoxia- and α-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas

Clinical Cancer Research

Volumn 16, Issue 24, 2010, Pages 6071-6082

  Kwon, Oh Joon ^a   Kim, Pyung Hwan ^a   Huyn, Steven ^b   Wu, Lily ^b   Kim, Minjung ^a   Yun, Chae Ok ^a,c  

^a Yonsei University College of Medicine   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; E1B PROTEIN; ONCOLYTIC ADENOVIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL KILLING; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNE RESPONSE; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; TUMOR MICROENVIRONMENT; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRIDAE; ALPHA-FETOPROTEINS; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS, GENETIC; SUBSTRATE SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650381982     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0664     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-16.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
4. Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 2008;15:877-84.
5. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going?J Natl Cancer Inst 1997;89:21-39.
6. Gene therapy clinical trials worldwide. J Gene Med 2009. Available from: http://www.wiley.co.uk/genetherapy/clinical.
7. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004;15:1022-33.
8. Kanerva A, Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004;110:475-80.
9. St George JA. Gene therapy progress and prospects: adenoviral vectors. Gene Ther 2003;10:1135-41.
10. Johnson M, Huyn S, Burton J, Sato M, Wu L. Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther 2006;17:1262-9.
11. Wood M, Perrotte P, Onishi E, Harper ME, Dinney C, Pagliaro L, et al. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 1999;6:367-72.
12. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007;254:178-216.
13. Green NK, Seymour LW. Adenoviral vectors: systemic delivery and tumor targeting. Cancer Gene Ther 2002;9:1036-42.
14. Kim J, Cho JY, Kim JH, Jung KC, Yun CO. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther 2002;9:725-36.
15. Ko D, Hawkins L, Yu DC. Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 2005;24:7763-74
16. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta 2008;395:19-26.
17. Sell S, Becker FF, Leffert HL, Watabe L. Expression of an oncodevelopmental gene product (alpha-fetoprotein) during fetal development and adult oncogenesis. Cancer Res 1976;36:4239-49.
18. Kew M. Alpha-fetoprotein in primary liver cancer and other diseases. Gut 1974;15:814-21.
19. Nakabayashi H, Hashimoto T, Miyao Y, Tjong KK, Chan J, Tamaoki T. A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma. Mol Cell Biol 1991;11:5885-93.
20. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/ radioresistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 2008;19:205-16.
21. 2 availability on human cancer. Nat Rev Cancer 2008;8:967-75.
22. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
23. Kanai F, Shiratori Y, Yoshida Y, Wakimoto H, Hamada H, Kanegae Y, et al. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology 1996;23:1359-68.
24. Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 1995;55:3105-9.
25. Takahashi M, Sato T, Sagawa T, Lu Y, Sato Y, Iyama S, et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 2002;5:627-34.
26. Kim J, Lee B, Kim JS, Yun CO, Kim JH, Lee YJ, et al. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells. Cancer Lett 2002;180:23-32.
27. Ohashi M, Kanai F, Tateishi K, Taniguchi H, Marignani PA, Yoshida Y, et al. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. Biochem Biophys Res Commun 2001;282:529-35.
28. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006;70:1469-80.
29. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ, et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997;3:515-20.
30. Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S, et al. Hypoxia-mediated tumour targeting. Gene Ther 2003;10:540-9.
31. Cho WK, Seong YR, Lee YH, Kim MJ, Hwang KS, Yoo J, et al. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther 2004;10:938-49.
32. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003; 22:2065-72.
33. Mazure NM, Chauvet C, Bois-Joyeux B, Bernard MA, Nacer-Cherif H, Danan JL. Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc. Cancer Res 2002;62:1158-65.
34. Shen BH, Hermiston TW. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther 2005;12:902-10.
35. Pipiya T, Sauthoff H, Huang YQ, Chang B, Cheng J, Heitner S, et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther 2005;12:911-7.
36. Ido A, Uto H, Moriuchi A, Nagata K, Onaga Y, Onaga M, et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res 2001;61:3016-21.
37. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
38. Kim E, Kim JH, Shin HY, Lee H, Yang JM, Kim J, et al. Ad-mTERTdelta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003;14:1415-28.
39. Jeong JS, Lee SW, Hong SH, Lee YJ, Jung HI, Cho KS, et al. Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model. Clin Cancer Res 2008;14:281-90.
40. Li ZY, Ni S, Yang X, Kiviat N, Lieber A. Xenograft models for liver metastasis: relationship between tumor morphology and adenovirus vector transduction. Mol Ther 2004;9:650-7.
41. Yin C, Lin Y, Zhang X, Chen YX, Zeng X, Yue HY, et al. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology 2008;48:1528-39.